chloroquine has been researched along with P carinii Pneumonia in 4 studies
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.
chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The widespread emergence of chloroquine-resistant Plasmodium falciparum led to the formulation of an effective, fixed combination of two antimalarial agents, pyrimethamine and the long-acting sulfonamide sulfadoxine, for prophylaxis and treatment." | 4.77 | Use of pyrimethamine-sulfadoxine (Fansidar) in prophylaxis against chloroquine-resistant Plasmodium falciparum and Pneumocystis carinii. ( Hewlett, EL; Pearson, RD, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gomes, A | 1 |
| Ferraz, R | 1 |
| Ficker, L | 1 |
| Collins, MS | 1 |
| Prudêncio, C | 1 |
| Cushion, MT | 1 |
| Teixeira, C | 1 |
| Gomes, P | 1 |
| Laurens, MB | 1 |
| Mungwira, RG | 1 |
| Nyirenda, OM | 1 |
| Divala, TH | 1 |
| Kanjala, M | 1 |
| Muwalo, F | 1 |
| Mkandawire, FA | 1 |
| Tsirizani, L | 1 |
| Nyangulu, W | 1 |
| Mwinjiwa, E | 1 |
| Taylor, TE | 1 |
| Mallewa, J | 1 |
| Blackwelder, WC | 1 |
| Plowe, CV | 1 |
| Laufer, MK | 1 |
| van Oosterhout, JJ | 1 |
| von Sonnenburg, F | 1 |
| Prüfer, L | 1 |
| Pearson, RD | 1 |
| Hewlett, EL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized, Open-label Controlled Trial of Daily Trimethoprim-sulfamethoxazole or Weekly Chloroquine Among Adults on Anti-retroviral Therapy in Malawi[NCT01650558] | 1,499 participants (Actual) | Interventional | 2012-11-30 | Completed | |||
| Dihydroartemisinin-Piperaquine or Sulphadoxine-Pyrimethamine for the Chemoprevention of Malaria in Children With Sickle Cell Anaemia in Eastern and Southern Africa: a Double Blind Randomised Trial (CHEMCHA)[NCT04844099] | Phase 3 | 723 participants (Actual) | Interventional | 2021-04-09 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Occurrence of adverse events that are greater than or equal to Grade 3 that require discontinuation of TS or CQ prophylaxis (NCT01650558)
Timeframe: 32-66 months
| Intervention | Events per 100 participant-years (Number) |
|---|---|
| Standard of Care Trimethoprim Sulfamethoxazol (TS) Prophylaxis | 0 |
| Chloroquine (CQ) Prophylaxis | 0.24 |
| Discontinuation of Standard of Care (Control Arm) | 0 |
Incidence of bacterial infections and malaria (NCT01650558)
Timeframe: 32-66 months
| Intervention | Events per 100 participant-years (Number) |
|---|---|
| Standard of Care Trimethoprim Sulfamethoxazol (TS) Prophylaxis | 27.8 |
| Chloroquine (CQ) Prophylaxis | 37.4 |
| Discontinuation of Standard of Care (Control Arm) | 36.3 |
Number of Participants with at Least One CD4 Count <200 (NCT01650558)
Timeframe: Every 6 months for 22-66 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Standard of Care Trimethoprim Sulfamethoxazol (TS) Prophylaxis | 24 |
| Chloroquine (CQ) Prophylaxis | 23 |
| Discontinuation of Standard of Care (Control Arm) | 27 |
Number of participants who ever have a detectable viral load (>400 copies/ml). (NCT01650558)
Timeframe: Throughout study participation, measured every six months (2-5.5 years).
| Intervention | Participants (Count of Participants) |
|---|---|
| Standard of Care Trimethoprim Sulfamethoxazol (TS) Prophylaxis | 24 |
| Chloroquine (CQ) Prophylaxis | 36 |
| Discontinuation of Standard of Care (Control Arm) | 33 |
Incidence of severe events (composite of death and WHO stage 3 and 4 illness) (NCT01650558)
Timeframe: 22-66 months
| Intervention | Events per 100 participant-years (Number) |
|---|---|
| Standard of Care Trimethoprim Sulfamethoxazol (TS) Prophylaxis | 3.3 |
| Chloroquine (CQ) Prophylaxis | 4.2 |
| Discontinuation of Standard of Care (Control Arm) | 4.2 |
Incidence of any WHO HIV stage 2, 3, or 4 illness (NCT01650558)
Timeframe: 32-66 months
| Intervention | Events per 100 participant-years (Number) |
|---|---|
| Standard of Care Trimethoprim Sulfamethoxazol (TS) Prophylaxis | 4.0 |
| Chloroquine (CQ) Prophylaxis | 5.7 |
| Discontinuation of Standard of Care (Control Arm) | 5.8 |
2 reviews available for chloroquine and P carinii Pneumonia
| Article | Year |
|---|---|
[Progress in immunodiagnosis and chemotherapy of protozoan infections].
Topics: Amebiasis; Animals; Antibodies; Babesiosis; Chloroquine; Drug Resistance, Microbial; Giardiasis; Hum | 1983 |
Use of pyrimethamine-sulfadoxine (Fansidar) in prophylaxis against chloroquine-resistant Plasmodium falciparum and Pneumocystis carinii.
Topics: Acquired Immunodeficiency Syndrome; Chloroquine; Drug Combinations; Drug Resistance; Humans; Malaria | 1987 |
1 trial available for chloroquine and P carinii Pneumonia
| Article | Year |
|---|---|
TSCQ study: a randomized, controlled, open-label trial of daily trimethoprim-sulfamethoxazole or weekly chloroquine among adults on antiretroviral therapy in Malawi: study protocol for a randomized controlled trial.
Topics: AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Anti-Retroviral Agents; Antimalarials; | 2016 |
1 other study available for chloroquine and P carinii Pneumonia
| Article | Year |
|---|---|
Chloroquine Analogues as Leads against Pneumocystis Lung Pathogens.
Topics: A549 Cells; Antimalarials; Cell Line, Tumor; Chloroquine; Humans; Immunocompromised Host; Pneumocyst | 2018 |